OA12279A - 2-Aminocarbonyl-9H-purine derivatives. - Google Patents

2-Aminocarbonyl-9H-purine derivatives. Download PDF

Info

Publication number
OA12279A
OA12279A OA1200200363A OA1200200363A OA12279A OA 12279 A OA12279 A OA 12279A OA 1200200363 A OA1200200363 A OA 1200200363A OA 1200200363 A OA1200200363 A OA 1200200363A OA 12279 A OA12279 A OA 12279A
Authority
OA
OAPI
Prior art keywords
compound
alkyl
formula
optionally substituted
piperidin
Prior art date
Application number
OA1200200363A
Other languages
English (en)
Inventor
Simon John Mantell
Peter Thomas Stephenson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014048A external-priority patent/GB0014048D0/en
Priority claimed from GB0024920A external-priority patent/GB0024920D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of OA12279A publication Critical patent/OA12279A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
OA1200200363A 2000-06-06 2001-06-05 2-Aminocarbonyl-9H-purine derivatives. OA12279A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0014048A GB0014048D0 (en) 2000-06-06 2000-06-06 Purine derivatives
GB0018246A GB0018246D0 (en) 2000-06-06 2000-07-25 Purine derivatives
GB0024920A GB0024920D0 (en) 2000-06-06 2000-10-11 Purine derivatives

Publications (1)

Publication Number Publication Date
OA12279A true OA12279A (en) 2003-01-01

Family

ID=27255754

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200363A OA12279A (en) 2000-06-06 2001-06-05 2-Aminocarbonyl-9H-purine derivatives.

Country Status (34)

Country Link
EP (1) EP1292604B1 (ko)
JP (2) JP4129176B2 (ko)
KR (1) KR100484704B1 (ko)
CN (1) CN1249074C (ko)
AR (1) AR030289A1 (ko)
AT (1) ATE431356T1 (ko)
AU (2) AU2001260537B2 (ko)
BG (1) BG107216A (ko)
BR (1) BR0111263A (ko)
CA (1) CA2414018C (ko)
CU (1) CU23240B7 (ko)
CZ (1) CZ20023875A3 (ko)
DE (1) DE60138702D1 (ko)
DK (1) DK1292604T3 (ko)
DZ (1) DZ3439A1 (ko)
EA (1) EA004983B1 (ko)
EE (1) EE200200678A (ko)
ES (1) ES2324816T3 (ko)
GC (1) GC0000287A (ko)
HK (2) HK1054042A1 (ko)
HR (1) HRP20020960A2 (ko)
HU (1) HUP0301330A3 (ko)
IL (2) IL152783A0 (ko)
IS (1) IS6599A (ko)
MA (1) MA26910A1 (ko)
MX (1) MXPA02012033A (ko)
NO (1) NO324426B1 (ko)
NZ (1) NZ522184A (ko)
OA (1) OA12279A (ko)
PA (1) PA8518801A1 (ko)
PL (1) PL360435A1 (ko)
SK (1) SK16752002A3 (ko)
TW (1) TWI227240B (ko)
WO (1) WO2001094368A1 (ko)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
GB0129270D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Pharmaceutical combination
US6974803B2 (en) 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
AU2003234716A1 (en) * 2002-04-10 2003-10-27 Joel M. Linden Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
US7067509B2 (en) 2003-03-07 2006-06-27 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
WO2004081005A1 (en) * 2003-03-07 2004-09-23 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
EP1685135B1 (en) 2003-10-21 2010-05-26 Inspire Pharmaceuticals, Inc. TETRAHYDRO-FURO[3,4-d]DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP2266994B1 (en) 2004-08-02 2013-04-03 University Of Virginia Patent Foundation 2-propynyl adenosine analgos with modified 5'-ribose groups having A2A agonist activity
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US8258141B2 (en) 2006-04-21 2012-09-04 Novartis Ag Organic compounds
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
KR20090075714A (ko) 2006-10-30 2009-07-08 노파르티스 아게 소염제로서의 헤테로시클릭 화합물
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
AR072166A1 (es) * 2008-06-19 2010-08-11 Takeda Pharmaceutical Derivado de piperidina y su uso como inhibidor de renina superior
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
SG175738A1 (en) 2009-05-29 2011-12-29 Pfizer Ltd Novel glucocorticoid receptor agonists
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
MY162604A (en) 2009-08-17 2017-06-30 Intellikine Llc Heterocyclic compounds and uses thereof
IN2012DN01453A (ko) 2009-08-20 2015-06-05 Novartis Ag
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914526A (pt) * 1998-10-16 2001-07-03 Pfizer Derivados de adenina
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives

Also Published As

Publication number Publication date
JP4129176B2 (ja) 2008-08-06
NO324426B1 (no) 2007-10-08
CN1434830A (zh) 2003-08-06
SK16752002A3 (sk) 2004-05-04
BG107216A (bg) 2003-05-30
CU23240B7 (es) 2007-10-17
CA2414018C (en) 2007-10-16
DK1292604T3 (da) 2009-06-15
MA26910A1 (fr) 2004-12-20
WO2001094368A1 (en) 2001-12-13
EA004983B1 (ru) 2004-10-28
JP2003535871A (ja) 2003-12-02
EE200200678A (et) 2004-06-15
MXPA02012033A (es) 2003-04-25
NO20025821D0 (no) 2002-12-04
DE60138702D1 (de) 2009-06-25
HK1089447A1 (en) 2006-12-01
BR0111263A (pt) 2003-06-17
HK1054042A1 (en) 2003-11-14
AU6053701A (en) 2001-12-17
KR20030032962A (ko) 2003-04-26
EP1292604A1 (en) 2003-03-19
NO20025821L (no) 2003-02-04
ATE431356T1 (de) 2009-05-15
CZ20023875A3 (cs) 2004-02-18
AU2001260537B2 (en) 2006-05-25
DZ3439A1 (fr) 2001-12-13
NZ522184A (en) 2004-05-28
TWI227240B (en) 2005-02-01
PL360435A1 (en) 2004-09-06
HUP0301330A3 (en) 2005-02-28
IL184144A (en) 2008-11-26
HUP0301330A2 (hu) 2003-08-28
IS6599A (is) 2002-10-29
CA2414018A1 (en) 2001-12-13
GC0000287A (en) 2006-11-01
PA8518801A1 (es) 2002-09-17
EA200201179A1 (ru) 2003-04-24
IL184144A0 (en) 2007-10-31
HRP20020960A2 (en) 2005-02-28
CN1249074C (zh) 2006-04-05
EP1292604B1 (en) 2009-05-13
AR030289A1 (es) 2003-08-20
ES2324816T3 (es) 2009-08-17
IL152783A0 (en) 2003-06-24
KR100484704B1 (ko) 2005-04-22
JP2008150383A (ja) 2008-07-03

Similar Documents

Publication Publication Date Title
OA12279A (en) 2-Aminocarbonyl-9H-purine derivatives.
AU764106B2 (en) Purine derivatives
AU2001260537A1 (en) 2-aminocarbonyl-9H-purine derivatives
US6350735B1 (en) Purine derivatives
US6448236B1 (en) Purine derivatives
US20060122145A1 (en) 2-Aminocarbonyl-9H-purine derivatives
WO2002022630A1 (en) Purine derivatives
NZ521867A (en) Purine derivatives
IL152783A (en) 2-aminocarbonyl-9h-purine derivatives